Intervention Review

You have free access to this content

Trifluoperazine versus placebo for schizophrenia

  1. Kai Koch1,*,
  2. Kamel Mansi2,
  3. Euan Haynes2,
  4. Clive E Adams2,
  5. Stephanie Sampson2,
  6. Vivek A Furtado3

Editorial Group: Cochrane Schizophrenia Group

Published Online: 11 JAN 2014

Assessed as up-to-date: 9 JAN 2013

DOI: 10.1002/14651858.CD010226.pub2

How to Cite

Koch K, Mansi K, Haynes E, Adams CE, Sampson S, Furtado VA. Trifluoperazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010226. DOI: 10.1002/14651858.CD010226.pub2.

Author Information

  1. 1

    The University of Nottingham, School of Medicine, Nottingham, Nottinghamshire, UK

  2. 2

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  3. 3

    Institute of Mental Health, Forensic Psychiatry, Nottingham, Nottinghamshire, UK

*Kai Koch, School of Medicine, The University of Nottingham, University Park, Queens Medical Centre, Nottingham, Nottinghamshire, UK.

Publication History

  1. Publication Status: New
  2. Published Online: 11 JAN 2014



References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Bishop 1964 {published data only}
  • Bishop MP, Gallant DM, Nesselhof W, Sprehe DJ. A controlled evaluation of butaperazine in chronic schizophrenic patients. Diseases of the Nervous System 1964;25:674-83.
Clark 1975 {published data only}
Gross 1974 {published data only}
  • Gross HS. A double-blind comparison of once-a-day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. Current Therapeutic Research, Clinical and Experimental 1974;16(7):696-705.
Gwynne 1962 {published data only}
Marjerrison 1964 {published data only}
  • Marjerrison G, Irvine D, Stewart CN, Williams R, Matheu H, Demay M. Withdrawal of long term phenothiazines from chronically hospitalized psychiatric patients. Canadian Psychiatric Association Journal 1964;60:290-8.
Menon 1972 {published data only}
  • Menon MS, Ramachandran V. A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Current Therapeutic Research 1972;14(1 January):17-21.
Pinard 1972 {published data only}
  • Pinard G, Prenoveau Y, Fliesen W, Elie R, Bielmann P, Lamontagne Y, et al. Pimozide and social rehabilitation of chronic schizophrenic patients [Le Pimozide et la reintegration sociale des schizophrenes chroniques]. L'Encephale 1972;61(1):53-66. [MEDLINE: 4561271]
Prien 1969* {published data only}
Reardon 1966 {published data only}
  • Reardon JD, Abrams S. Acute paranoid schizophrenia (treatment with chlorpromazine, trifluoperazine and placebo). Diseases of the Nervous System 1966;27:265-70.
Schiele 1961 {published data only}
  • Schiele BC, Vestre ND, Stein KE. A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. Journal of Clinical and Experimental Psychopathology 1961;22(3):151-62. [MEDLINE: 14498342]

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Abuzzahab 1977 {published data only}
  • Abuzzahab FS. The treatment of schizophrenia with long-acting oral neuroleptics: a six-month double-blind investigation of penfluridol versus trifluoperazine. Psychopharmacology Bulletin 1977;13(3):26-7. [MEDLINE: 329326]
Barron 1961 {published data only}
  • Barron A, Beckering B, Rudy LH, Smith JA. A "double-blind" study comparing RO 4-0403, trifluoperazine and a placebo in chronically ill mental patients. American Journal of Psychiatry 1961;118:347-8.
Cahan 1960 {published data only}
Coons 1962 {published data only}
  • Coons WH, Boyd BA, White JG. Chlorpromazine, trifluoperazine and placebo with long term mental hospital patients. Canadian Psychiatric Association Journal 1962;7:159-63.
Hamilton 1963 {published data only}
  • Hamilton M, Hordern A, Waldrop FN, Lofft J. A controlled trial on the value of prochlorperazine, trifluoperazine and intensive group treatment. British Journal of Psychiatry 1963;109:510-22.
Holden 1971 {published data only}
  • Holden J, Itil T, Gannon P, Keskiner A. The clinical effects of intramuscular thiothixene and trifluoperazine in chronic schizophrenia: a comparative study. Current Therapeutic Research, Clinical and Experimental 1971;13(5):298-310. [MEDLINE: 71276382]
Hunt 1967 {published data only}
Leff 1971 {published data only}
Leff 1973 {published data only}
Madgwick 1958 {published data only}
  • Madgwick JRA, McNeill DLM, Driver M, Preston GC. Stelazine (trifluoperazine). A preliminary report on a clinical trial. Journal of Mental Science 1958;104:1195-8.
Morton 1968 {published data only}
Stanley 1961 {published data only}
  • Stanley WJ, Walton D. Trifluoperazine (stelazine). A controlled clinical trial in chronic schizophrenia. Journal of Mental Science 1961;107:250-7.
Weckowicz 1960 {published data only}
Weston 1961 {published data only}
  • Weston FK, Loftus AP. A terminal double-blind trial of tri-fluoperazine ("stelazine") in chronic schizophrenia. Medical Journal of Australia 1961;48(1):776-80. [MEDLINE: 13784630]

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Ortega-Soto 1996 {published data only}
  • Ortega-Soto HA, Brunner E, Apiquian R, de la Torre MP, Ulloa RE. Typical antipsychotics: the threshold doses strategy. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Altman 1996
Arana 2000
  • Arana G, Rosenbaum J. Handbook of Psychiatric Drug Therapy. USA. 4. Philadelphia: Lippincott Williams and Wilkins, 2000.
Bartko 1988
Bazire 2000
Bland 1997
BNF 2012
  • BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF 2012.
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
  • Cost-Effectiveness Analysis Registry (CEA). accessed 11/09/13.
Davies 2007
  • Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 2007;191:14-22.
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Divine 1992
Donner 2002
Drummond 1996
Egger 1997
Elbourne 2002
  • Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
Evers 2005
  • Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. International Journal of Technology Assessment in Health Care 2005;21(2 Spring):240-5.
Farina 1957
Filippelli 2005
  • Filippelli E, Biricolti G, Scarano C, Russo F, Luciano L. Treatment of psychotic disorders with olanzapine, risperidone and typical neuroleptics: a comparative cost-effectiveness evaluation in a local psychiatric setting. Farmeconomia e Percorsi Terapeutici 2005;6(3):161-8.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
Galvin 1999
  • Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clinical Therapeutics 1999;21(6):1105-16.
Ghaemi 2001
  • Ghaemi SN, Kirkwood CK, Sambur MR, Ko JY, Howden KL, Duong Q, et al. Economic outcomes of risperidone in comparison to typical neuroleptic agents for treatment-resistant psychosis: a community-based study. Journal of Pharmacy Technology 2001;17:273-8.
Goodrich 1953
Gulliford 1999
  • Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
Guy 1970
  • Guy W, Bonato RR. Clinical Global Impressions. In: Guy W, Bonato RR editor(s). Manual for the ECDEU Assessment Battery. 2 Rev. National Institute of Mental Health, 1970:12-1-12-6.
Hanrahan 2006
  • Hanrahan P, Luchins DJ, Fabian R, Tolley G. Cost-effectiveness of atypical antipsychotic medications versus conventional medication. Expert Opinion in Pharmacotherapy 2006;7(13):1749-58.
Hathaway 1940
  • Hathaway SR, McKinley JC. A multiphasic personality schedule (Minnesota): I. Construction of the schedule. Journal of Psychology 1940;10:249-54.
HES 2012
  • Hospital Episode Statistics, Admitted Patient Care - England 2011-12: Main Specialties (.xls). (accessed May 2013) 2011-12.
Higgins 2003
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from
Kaplan 1998
  • Kaplan H, Sadock B. Pocket Handbook of Clinical Psychiatry. USA. 2. New York: Williams and Wilkins, 1998.
Kay 1986
  • Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
Knapp 2008
  • Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. PharmacoEconomics 2008;26(4):341-58.
Lankappa 2012
  • Lankappa S, Gandhi R. Quetiapine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD009935]
Leucht 2003
Leucht 2005
Leucht 2005a
  • Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
Leucht 2007
  • Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
Lewis 1998
  • Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Canadian Journal of Psychiatry 1998;43(6):596-604.
Lewis 2006
  • Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment 2006;10(17):1-182.
Lorr 1960
Mangalore 2007
Marshall 2000
  • Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
Martin 2006
  • Martin JL, Perez V, Sacristan M, Rodriguez-Artalejo F, Martinez C, Alvarez E. Meta-analysis of drop-out rates in randomised clinical trials, comparing typical and atypical antipsychotics in the treatment of schizophrenia. European Psychiatry 2006;21(1):11-20.
Mendelsohn 1959
  • Mendelsohn RM, Penman AS, Schiele BC. Massive chlorpromazine therapy: the nature of behavioural changes. Psychiatric Quarterly 1959;33(Jan):1-22.
Mental Health Care
  • Mental Health Care: reliable and up-to-date information about psychosis for family members and friends. accessed September 2013.
Moher 2001
  • Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(12):1987-91.
Mould 2009
  • Mould QJ, Contreras HI, Verduzco W, Mejia AJM, Garduno EJ. Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics. Revista de Psiquiatrí́a y Salud Mental 2009;2(3):108-18.
NICE 2010
  • NICE. Schizophrenia: Core interventions in the treatment and management in adults in primary and secondary care - National Clinical Guideline Number 82. The British Psychological Society and The Royal College of Psychiatrists, 2010:4-41.
Overall 1962
PJ Online
  • PJ Online: Do you accept that medicine shortages have not harmed patients?. Accessed September 2013.
PSSRU 2012
  • Compiled by Lesley Curtis. Unit costs of health and social care 2012. (accessed May 2013) 2012:47.
  • Royal College of Psychiatrists. Antipsychotics. RCPSYCH 2009.
  • Royal College of Psychiatrists. Schizophrenia. RCPSYCH 2010.
  • Royal College of Psychiatrists. Schizophrenia. RCPSYCH 2011.
Saha 2005
Saha 2007
Schünemann 2008
  • Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
Stargardt 2008
  • Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Journal of Mental Health Policy and Economics 2008;11(2):89-97.
Suttajit 2009
Tiihonen 2009
  • Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374(9690):620-7.
Turner 2007
  • Turner T. Chlorpromazine: unlocking psychosis. BMJ 2007;334(Suppl 1):s7.
Ukoumunne 1999
  • Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
Williams 1987
  • Williams, A (editor). Health economics: the cheerful face of dismal science?. Health and economics. London (UK): Macmillan, 1987.
Wing 1961
Xia 2009
  • Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Marques 2004
  • Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD003545; PUBMED: 14974020]